Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLPH Bellerophon Therapeutics	$0.01	$0.02	$0.01 ▼ $0.02	$147K	0.74	18,907 shs	7,027 shs
TRVN Trevena	$0.25 +20,733.3%	$0.70	$0.00 ▼ $7.85	$240K	0.41	2,160 shs	6,905 shs
VINC Vincerx Pharma	$0.03 -24.9%	$0.04	$0.03 ▼ $17.00	$170K	1.71	556,241 shs	145,819 shs
WINT Windtree Therapeutics	$0.09 -3.0%	$0.61	$0.09 ▼ $487.50	$341K	0.63	5.76 million shs	216,668 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLPH Bellerophon Therapeutics	0.00%	0.00%	0.00%	0.00%	-65.71%
TRVN Trevena	-99.56%	-99.56%	-99.87%	-99.90%	-99.97%
VINC Vincerx Pharma	-14.60%	+14.85%	+8.25%	-10.72%	-99.73%
WINT Windtree Therapeutics	-6.29%	-28.25%	-87.94%	-87.45%	-99.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLPH Bellerophon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	1.2598 of 5 stars	3.0	2.0	0.0	0.0	0.0	0.0	0.6
VINC Vincerx Pharma	2.4959 of 5 stars	3.5	3.0	0.0	0.0	0.6	1.7	1.3
WINT Windtree Therapeutics	2.2744 of 5 stars	3.0	4.0	0.0	0.0	2.0	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLPH Bellerophon Therapeutics	0.00	N/A	N/A	N/A
TRVN Trevena	2.00	Hold	$5.00	1,900.00% Upside
VINC Vincerx Pharma	3.00	Buy	$40.00	122,976.92% Upside
WINT Windtree Therapeutics	2.00	Hold	$350.00	375,839.85% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLPH Bellerophon Therapeutics	$5.64M	0.03	N/A	N/A	$0.27 per share	0.04
TRVN Trevena	$443K	0.54	N/A	N/A	($11.07) per share	-0.02
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$10.50 per share	N/A
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	$0.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLPH Bellerophon Therapeutics	-$19.83M	-$0.84	N/A	∞	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	11/5/2025 (Estimated)
VINC Vincerx Pharma	-$40.16M	-$20.60	N/A	N/A	N/A	N/A	-248.33%	-132.73%	9/4/2025 (Estimated)
WINT Windtree Therapeutics	-$1.79M	-$823.47	N/A	N/A	N/A	N/A	-207.34%	-50.19%	N/A

Latest BLPH, WINT, VINC, and TRVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/19/2025	Q2 2025	WINT Windtree Therapeutics	-$99.00	-$3.06	+$95.94	-$3.06	$3.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLPH Bellerophon Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLPH Bellerophon Therapeutics	N/A	N/A	N/A
TRVN Trevena	N/A	2.42	2.42
VINC Vincerx Pharma	N/A	2.17	2.17
WINT Windtree Therapeutics	N/A	0.43	0.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLPH Bellerophon Therapeutics	10.61%
TRVN Trevena	13.56%
VINC Vincerx Pharma	44.02%
WINT Windtree Therapeutics	29.33%

Insider Ownership

Company	Insider Ownership
BLPH Bellerophon Therapeutics	5.20%
TRVN Trevena	2.70%
VINC Vincerx Pharma	15.60%
WINT Windtree Therapeutics	0.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLPH Bellerophon Therapeutics	20	12.23 million	11.60 million	No Data
TRVN Trevena	40	959,000	841,000	Optionable
VINC Vincerx Pharma	60	5.23 million	1.89 million	Not Optionable
WINT Windtree Therapeutics	30	3.66 million	3.66 million	Not Optionable

BLPH, WINT, VINC, and TRVN Headlines

Recent News About These Companies

Warrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ Delisting

August 27 at 4:48 PM | msn.com

BNB Treasury Firm Windtree Therapeutics Plunges 77% After Nasdaq Delisting Notice

August 22, 2025 | thecurrencyanalytics.comT

BNB treasury company plunges 77% after Nasdaq delisting notice

August 22, 2025 | cointelegraph.com

BNB hits new all-time high even as treasury company Windtree Therapeutics faces Nasdaq delisting

August 20, 2025 | fxstreet.com

Nasdaq to Delist BNB Treasury Firm Windtree Therapeutics, Stock Crashes 76%

August 20, 2025 | coingape.comC

Windtree Therapeutics Faces Nasdaq Delisting Notice

August 20, 2025 | msn.com

Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

August 20, 2025 | americanbankingnews.com

Windtree Therapeutics Delays Q2 2025 Report Filing

August 14, 2025 | tipranks.com

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

August 11, 2025 | globenewswire.com

Windtree Therapeutics Terminates SEISMiC-C Clinical Study

August 11, 2025 | theglobeandmail.com

Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results

August 7, 2025 | msn.com

Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

August 5, 2025 | taiwannews.com.twT

Windtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy Rollout

July 30, 2025 | msn.com

Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

July 29, 2025 | globenewswire.com

Windtree Therapeutics Bets $520M on Binance Coin in Unprecedented Crypto Pivot

July 26, 2025 | thecurrencyanalytics.comT

Windtree Therapeutics Commits Up to $700 Million to Build BNB Treasury Following All-Time High

July 26, 2025 | techstory.inT

Windtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency Holdings

July 26, 2025 | msn.com

Windtree Therapeutics Targets $520 Million in Funding to Secure BNB Reserve

July 25, 2025 | beincrypto.comB

Nasdaq-listed Windtree Therapeutics Commits $520M to BNB in Bold Treasury Pivot

July 25, 2025 | blockonomi.com

Windtree Therapeutics Taps $520M to Build BNB Reserves — Is Pharma Going Crypto?

July 25, 2025 | crypto-news-flash.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLPH, WINT, VINC, and TRVN Company Descriptions

Bellerophon Therapeutics NASDAQ:BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Trevena NASDAQ:TRVN

$0.25 +0.25 (+20,733.33%)

As of 02:24 PM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Vincerx Pharma NASDAQ:VINC

$0.03 -0.01 (-24.94%)

As of 03:26 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Windtree Therapeutics NASDAQ:WINT

$0.09 0.00 (-3.02%)

As of 02:53 PM Eastern

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time